Kasturi Haldar Rev. Julius A. Nieuwland, C.S.C. Professor; Parsons-Quinn Director, CRND
Our goal is to convert research findings into therapeutics in rare, inherited disorders as well as neglected infectious diseases. These diseases have generally been ignored by the pharmaceutical industry because the financial rewards for developing new drugs and vaccines to treat them are so insignificant.
In rare diseases we focus on neurological disorders such as Niemann Pick Type C (NP-C) and other disorders that result in neurodegenerative disease. We study inflammatory lipid mobilization in diseased cells and develop biomarkers and new therapies in preclinical murine models with the goal of moving treatments to phase I human clinical studies.
The laboratory has had a long standing interest in malaria. A major emphasis is the human malaria parasite Plasmodium falciparum, which invades and develops in red blood cells to cause disease pathologies that include severe malarial anemia and cerebral disease. The present focus is the molecular mechanism of resistance to artemisinin and new drugs to replace them, since resistance to these front line antimalarials threatens global malaria control and elimination
To accelerate the development of therapies we partner with pharmaceutical companies in innovative models of private public partnerships in rare and neglected diseases.
- Rev. Julius A. Nieuwland C.S.C. Professor of Biological Sciences
- James Parsons and Carrie Quinn Director, Boler-Parseghian Center for Rare and Neglected Diseases
- Charles and Emma Morrison Professor of Pathology, Northwestern University School of Medicine 1999-2008
- Associate Professor, Department Microbiology-Immunology, Stanford University 1994-1998
- Assistant Professor, Department Microbiology-Immunology, Stanford University 1988-1994
- Postdoctoral Associate. Rockefeller University, 1985-1988
- Foreign Expert, Peking Union Medical College, Beijing China, 1984-1985
- Postdoctoral Fellow. Rockefeller University, 1984-1985
- Ph. D. Biochemistry (Dept of Chemistry, Massachusetts Institute of Technology.
- Haldar K. 2015 From Cell and Organismal Biology to Drugs. PLoS Pathogens 11(6):e1005002. doi: 10.1371/journal.ppat.1005002.
- Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, Rizk SS, Njimoh DL, Ryan Y, Chotivanich K, Nguon C, Ghorbal M, Lopez-Rubio JJ, Pfrender M, Emrich S, Mohandas N, Dondorp AM, Wiest O, Haldar K (2015) A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. Apr 30;520(7549):683-7. doi: 10.1038/nature14412.
- Safeukui I, Gomez ND, Adelani AA, Burte F, Afolabi NK, Akondy R, Velazquez P, Holder A, Tewari R, Buffet P, Brown BJ, Shokunbi WA, Olaleye D, Sodeinde O, Kazura J, Ahmed R, Mohandas N, Fernandez-Reyes D, Haldar K. 2015 Malaria induces anemia through CD8+ T cell-dependent parasite clearance and erythrocyte removal in the spleen. MBio . 2015 Jan 20;6(1). pii: e02493-14. doi: 10.1128/mBio.02493-14.
- Rajasimha HK, Shirol PB, Ramamoorthy P, Hegde M, Barde S, Chandru V, Ravinandan ME, Ramchandran R, Haldar K, Lin JC, Babar IA, Girisha KM, Srinivasan S, Navaneetham D, Battu R, Devarakonda R, Kini U, Vijayachandra K, Verma IC. 2014 Organization for rare diseases India (ORDI) - addressing the challenges and opportunities for the Indian rare diseases' community. Genet Res (Camb). Aug 13;96:e009. doi: 10.1017/S0016672314000111.
- Fru-Cho J, Bumah VV, Safeukui I, Nkuo-Akenji T, Titanji VP, Haldar K. 2014 Molecular typing reveals substantial Plasmodium vivax infection in asymptomatic adults in a rural area of Cameroon. Malar J. 2014 May 3;13:170. doi: 10.1186/1475-2875-13-170.
- Jauréguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, Biligui S, Ciceron L, Mouri O, Kendjo E, Bricaire F, Vray M, Angoulvant A, Mayaux J, Haldar K, Mazier D, Danis M, Caumes E, Thellier M, Buffet P; French Artesunate Working Group. 2014 Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood. Jul 10;124(2):167-75. doi: 10.1182/blood-2014-02-555953. Epub 2014 May 23.
- Alam MS, Getz M, Yi S, Kurkewich J, Safeukui I, Haldar K.2014 Plasma signature of neurological disease in the monogenetic disorder Niemann-Pick Type C. J Biol Chem. 289(12):8051-66. doi: 10.1074/jbc.M113.526392.
- Bhattacharjee S, Stahelin RV, Speicher KD, Speicher DW, Haldar K.2012 Endoplasmic reticulum PI(3)P lipid binding targets malaria proteins to the host cell. Cell. 2012 148(1-2):201-12.
- Shin J, Epperson K, Yanjanin NM, Albus J, Borgenheimer L, Bott N, Brennan E, Castellanos D, Cheng M, Clark M, Devany M, Ensslin C, Farivari N, Fernando S, Gabriel L, Gallardo R, Castleman M, Gutierrez O, Herschel A, Hodge S, Horst A, Howard M, James E, Jones L, Kearns M, Kelly M, Kim C, Kiser K, Klazura G, Knoedler C, Kolbus E, Lange L, Lee J, Li E, Lu W, Luttrell A, Ly E, McKeough K, McSorley B, Miller C, Mitchell S, Moon A, Moser K, O'Brien S, Olivieri P, Patzwahl A, Pereira M, Pymento C, Ramelb E, Ramos B, Raya T, Riney S, Roberts G, Robertshaw M, Rudolf F, Rund S, Sansone S, Schwartz L, Shay R, Siu E, Spear T, Tan C, Truong M, Uddin M, Vantrieste J, Veloz O, White E, Porter FD, Haldar K. 2011 Defining natural history: assessment of the ability of college students to aid in characterizing clinical progression of Niemann-Pick disease, type C. PLoS One. 2011;6(10):e23666. doi: 10.1371/journal.pone.0023666.